Clinical Trial Update: A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies [Phase 2]

View source ↗

Summary

Phase II study evaluating lenvatinib with pembrolizumab in metastatic gastroesophageal and gastric cancer after prior therapies; study completed with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Cancer

Drugs mentioned

• Lenvatinib (lenvatinib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: NYU Langone Health | Conditions: GastroEsophageal Cancer, Gastric Cancer | Phase 2 | Status: COMPLETED | Results posted: 2024-03-27